Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 432c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($4.32). Revenue for the quarter came in at $37.93 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Waller: Recent Increases In Core Inflation Are Quite Broad
• JD.com, Inc (JD) PT Lowered to $37 at Macquarie ahead of earnings
• United States Oil Fund (USO) call put ratio 1.4 calls to 1 put as WTI crude oil trades $74.90